Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Nelson B. Watts; John P. Bilezikian; Keith Usiskin; Robert Edwards; Mehul Desai; Gordon Law; Gary Meininger

doi:10.1210/jc.2015-3167

Abstract

Fracture risk was increased with canagliflozin treatment, driven by CANVAS patients, who were older, with a prior history/risk of cardiovascular disease, and with lower baseline estimated glomerular filtration rate and higher baseline diuretic use. The increase in fractures may be mediated by falls; however, the cause of increased fracture risk with canagliflozin is unknown.

Keywords

CanagliflozinMedicineType 2 Diabetes MellitusDiabetes mellitusInternal medicineType 2 diabetesEndocrinology

Affiliated Institutions

Related Publications

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial

Bruce Neal , Vlado Perkovic , David R. Matthews +10 more

Aims The primary aim of the CANagliflozin cardioVascular Assessment Study‐Renal (CANVAS‐R) is to determine whether the favourable effects of inhibition of the sodium glucose co‐...

2017 Diabetes Obesity and Metabolism 160 citations

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal , Vlado Perkovic , Kenneth W. Mahaffey +7 more

Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We ...

2017 New England Journal of Medicine 7382 citations

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Bruce Neal , Vlado Perkovic , Dick de Zeeuw +9 more

Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered ...

2013 American Heart Journal 330 citations

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

John J.V. McMurray , David L. DeMets , Silvio E. Inzucchi +9 more

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...

2019 European Journal of Heart Failure 430 citations

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse , Deborah J. Wexler , Απόστολος Τσάπας +5 more

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on...

2019 Diabetes Care 1135 citations

Publication Info

Year: 2015
Type: article
Volume: 101
Issue: 1
Pages: 157-166
Citations: 430
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

430

OpenAlex

Cite This

APA Style

                            
                                
                                    Nelson B. Watts, 
                                
                                    John P. Bilezikian, 
                                
                                    Keith Usiskin
                                
                                et al.
                            
                            (2015). 
                            Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. 
                            The Journal of Clinical Endocrinology & Metabolism
                            , 101
                            (1)
                            , 157-166.
                            https://doi.org/10.1210/jc.2015-3167
                        

Identifiers

DOI: 10.1210/jc.2015-3167